Saluda Medical: Business Overview, Financials & Competitive Analysis
Saluda Medical scores 7/10 on the AskCyborg Cyborg Score (Strong). Closed-loop spinal cord stimulation leader with clinical validation and institutional backing, transitioning from development to commercial scale in a large, underserved chronic pain market. Published clinical evidence in top-tier journals demonstrates superiority and long-term pain relief improvements, with $530M in funding from major investors like Boston Scientific. As of April.
What is Saluda Medical's industry? Saluda Medical (saludamedical.com) operates in Neurostimulation Devices. AskCyborg classifies Saluda Medical under Neurostimulation Devices in its company registry.
Saluda Medical is a global company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders...
Cyborg Score thesis
Closed-loop spinal cord stimulation leader with clinical validation and institutional backing, transitioning from development to...
Read the full analyst-debate transcript →Get the Latest Saluda Medical Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSaluda Medical Overview
Pro stress-test →Saluda Medical is a global company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders. The company's first product, the Evoke® System, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system and is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain.
Strategic Profile
Pro stress-test →The Evoke System instantaneously reads, records, and responds to the nerves' response to stimulation to provide continually optimized therapy and is proven to be superior to open-loop SCS for the treatment of overall trunk and/or limb pain. 12-month results from the EVOKE Study, the first double-blind randomized controlled trial (RCT) used in support of Premarket Approval (PMA) in spinal cord stimulation history, were published in The Lancet Neurology and 24-month results have since been published JAMA Neurology. Saluda Medical's latest funding was a Series F round on October 30, 2025, positioning the company for expanded commercialization.
Competitive Landscape
Pro stress-test →Saluda Medical competes with companies including Nalu Medical, Nuvectra and Clearing in the neuromodulation space. As the only ECAP-controlled closed-loop SCS player with published clinical superiority data, Saluda holds differentiation versus traditional open-loop competitors. The market is dominated by established players offering open-loop systems, creating opportunity for closed-loop innovation.
Industry Context
Saluda Medical operates in Neurostimulation Devices.
Key facts
Founded: 2010 · Headquarters: Bloomington, Minnesota, US · Employees: 483 · Revenue: $20.2M (2026)